546 related articles for article (PubMed ID: 26294332)
21. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
25. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Grimwade D; Jovanovic JV; Hills RK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
[TBL] [Abstract][Full Text] [Related]
26. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
27. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
29. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
31. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
32. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
35. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
Iaccarino L; Ottone T; Alfonso V; Cicconi L; Divona M; Lavorgna S; Travaglini S; Ferrantini A; Falconi G; Baer C; Usai M; Forghieri F; Venditti A; Del Principe MI; Arcese W; Voso MT; Haferlach T; Lo-Coco F
Am J Hematol; 2019 Oct; 94(10):1091-1097. PubMed ID: 31292998
[TBL] [Abstract][Full Text] [Related]
36. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
37. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Grimwade D; Jovanovic JV; Hills RK; Nugent EA; Patel Y; Flora R; Diverio D; Jones K; Aslett H; Batson E; Rennie K; Angell R; Clark RE; Solomon E; Lo-Coco F; Wheatley K; Burnett AK
J Clin Oncol; 2009 Aug; 27(22):3650-8. PubMed ID: 19506161
[TBL] [Abstract][Full Text] [Related]
38. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
39. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
40. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
Gallagher RE; Schachter-Tokarz EL; Zhou DC; Ding W; Kim SH; Sankoorikal BJ; Bi W; Livak KJ; Slack JL; Willman CL
Leukemia; 2006 Apr; 20(4):556-62. PubMed ID: 16437139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]